Abstract Library

#2157 A Case Report of a Well-Differentiated Neuroendocrine Tumor in which Sunitinib Treatment Resulted an Effective Response of Disease

Introduction: A case report of no pancreatic well-differentiated neuroendocrine tumor in which sunitinib treatment resulted an effective response of disease

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: SAI R,

Keywords: WD NET, SUNITINIB, NO pNET, Efficacy and safety,

#2017 Data on Healthcare Resource Utilization (HCRU) and Treatment Modalities in Patients (Pts) with Advanced (adv), Well-Differentiated (WD) Neuroendocrine Tumors (NETs) of Gastrointestinal (GI) or Lung Origin in Finland

Introduction: The majority of all NETs develop in the GI tract and about one third develop in the lungs; approximately 43% and 51% of pts, respectively, are diagnosed with adv disease (regional or distant metastasis). While GI and lung NETs are rare, their incidence has increased markedly over the past four decades. The severe and progressive nature of adv NET suggests significant costs for pts and payers.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Gaasvik L, Aavikko M, Kurki S, Oddershede L,

Keywords: NET, HCRU, GI, Lung,

#1337 O6-Methylguanine DNA Methyltransferase (MGMT) Deficiency and Response to Aranoza-Based Therapy in Patients with Neuroendocrine Tumors

Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ. O6-methylguanine DNA methyltransferase (MGMT) is an enzyme implicated in chemotherapy resistance to alkylating agents and its low levels are associated with sensitivity to them.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Polozkova S, Stepanova E, Delektorskaya V, Kozlov N, Gorbunova V,

Keywords: aranoza, MGMT, chemotherapy, NETs,

#1275 Aranoza in the Treatment of Metastatic Neuroendocrine Tumors (NETs): Single Institution Experience

Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Gorbunova V, Orel N, Kuzminov A, Emelianova G, Odintsova A,

Keywords: aranoza, Neuroendocrine tumors, chemotherapy,

#1120 Retrospective Comparison of Chemotherapy Treatment with Capecitabine Alone or Fluropirimidine Plus Oxaliplatin in Advanced and Pretreated NET

Introduction: Oxaliplatine plus fluoropirimidine and capecitabine treatment alone are considered investigational treatments in well-differentiated (WD) NET

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Marconcini R

Authors: Marconcini R, Ricci S, Galli L, Antonuzzo A, Vasile E,

Keywords: capecitabine, oxaliplatine ,